Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24180195 | 0.85 | PARP15 (0.55) | SIGMAR1PARP15PARP10PARP2DRD2 | |
| SCHEMBL5525582 | 0.82 | CARM1 (0.48) | PARP15PARP10PARP2 | |
| SCHEMBL25727749 | 0.82 | PARP15 (0.57) | PARP15PARP10PARP2LTA4H | |
| SCHEMBL7034688 | 0.81 | SIGMAR1 (0.45) | SIGMAR1DRD2DRD4LTA4H | |
| SCHEMBL8573618 | 0.77 | LTA4H (0.63) | PARP15PARP10PARP2LTA4H | |
| SCHEMBL8285615 | 0.77 | PARP15 (0.51) | PARP15PARP10PARP2DRD2DRD4 | |
| SCHEMBL1475391 | 0.77 | TDP1 (0.68) | LTA4H | |
| SCHEMBL5515434 | 0.77 | — | — | |
| SCHEMBL5524936 | 0.77 | HPGD (0.46) | — | |
| Hydrochloric Acid SCHEMBL1476773 | 0.76 | TDP1 (0.71) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | SIGMAR1 115/4885PARP15 3115/4885PARP10 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.